Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

WVE-004

Oligonucleotide (Antisense oligonucleotide) · Gene silencing · developed by Wave Life Sciences

Phase 1/2 Most advanced trial (none active)

WVE Developer

2 Registered trials

What is WVE-004?

WVE-004 is a stereopure antisense oligonucleotide administered by intrathecal injection. It is being studied in amyotrophic lateral sclerosis and frontotemporal dementia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Oligonucleotide (Antisense oligonucleotide)
Mechanism: Gene silencing
Therapy area: Neurology
Developer: Wave Life Sciences (WVE)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05683860	Phase 1/2	Amyotrophic Lateral Sclerosis	Terminated	WVE
NCT04931862	Phase 1/2	ALS	Terminated	WVE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

ALSAmyotrophic Lateral SclerosisFrontotemporal DementiaFTD

More from Wave Life Sciences

WVE-003 Phase 1/2 WVE-006 Phase 1/2 WVE-007 Phase 1/2 WVE-120101 Phase 1/2 WVE-120102 Phase 1/2 WVE-210201 Phase 2/3 WVE-N531 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the WVE page.

Follow WVE, the company behind WVE-004

See WVE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

WVE catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z